ReCode Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1140 Obrien Dr, Menlo Park, California, ...Phone Number
(408) 585-1700Website
www.recodetx.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company pioneering targeted delivery of genetic therapies using their proprietary SORT lipid nanoparticle platform to treat rare and common diseases with precision and improved efficacy.Explore more
ReCode Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ReCode Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at ReCode Therapeutics
Check if ReCode Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if ReCode Therapeutics had a recent Job posting/layoffs
ReCode Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ReCode Therapeutics is spiking on competitors!
Earning: See what the market has to say on ReCode Therapeutics recently announced quarterly report
Product Launch: Get notified when ReCode Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once ReCode Therapeutics has new funding data
Recommended Actions
Reach out to Masked Content who joined ReCode Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to ReCode Therapeutics
Compare insights from companies similar to ReCode Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ReCode Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ReCode Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ReCode Therapeutics.
ReCode Therapeutics financials insights
Gather financial insights about ReCode Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Angel/Seed
$2M
2020
Series A
$80M
2023
Private Equity
$15M
Series B
$260M
2025
Other Financing Round
$29M
Debt
$29.4M
ReCode Therapeutics Tech Stack
A closer look at the technologies used by ReCode Therapeutics
Most Recent Scoops
Person-Based
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Funding, Pharmaceuticals, Clinical Operations, Finance
Person-Based
ReCode Therapeutics News & Media
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, announced today that it will receive new funding from the Cystic Fibrosis Foundation (CF Foundation) to support ReCode’s gene correction research program with the goal of developing and commercializing new treatments for people with cystic fibrosis (CF), including those with genotypes that do not respReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today presented preclinical data from its mRNA-based cystic fibrosis (CF) program at the North American Cystic Fibrosis Conference (NACFC), taking place September 26-28, 2024, in Boston, Massachusetts. These preclinical data demonstrate that RCT2100 significantly restored CFTR function in human bronchReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the first patient has been dosed in a Phase 1b study evaluating RCT2100, an investigational inhaled mRNA therapy for people with cystic fibrosis (CF). CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, impacting approximately 130,000ReCode Therapeutics to Participate in Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the following upcoming conferences: Chardan’s 8th Annual Genetic Medicines Conference Format: Panel, Presentation and 1x1 Investor Meetings Date: September 30, 2024 Company Presentation Time: 9:00 am – 9:30 am EST Panel Participation: Next Ge
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ReCode Therapeutics
Sign Up For FreeTo access detailed company insights
ReCode Therapeutics is a clinical-stage genetic medicines company pioneering targeted delivery of genetic therapies using their proprietary SORT lipid nanoparticle platform to treat rare and common diseases with precision and improved efficacy.... Read More
